Squamous Cell Carcinoma News and Research

RSS

Squamous Cell Carcinoma is cancer that begins in squamous cells, which are thin, flat cells that look like fish scales. Squamous cells are found in the tissue that forms the surface of the skin, the lining of the hollow organs of the body, and the passages of the respiratory and digestive tracts. Also called epidermoid carcinoma.

Low-cost handheld device could cut the rate of unnecessary skin biopsies

Skin biopsies are no fun: doctors carve away small lumps of tissue for laboratory testing, leaving patients with painful wounds that can take weeks to heal.

5 May 2022

MAPK pathway mutations can provide “precision” treatment targets for head and neck cancer

About one-fifth of often deadly head and neck cancers harbor genetic mutations in a pathway that is key to normal cell growth, and scientists report those mutations, which enable abnormal cancer cell growth, can also make the cancer vulnerable.

28 Apr 2022

New therapeutic option for HPV-positive head and neck carcinoma discovered

The various manifestations of head and neck carcinomas rank sixth in frequency worldwide and are fatal for about half a million people every year. In a quarter of cases, head and neck squamous cell carcinoma (HNSCC) is caused by human papillomavirus (HPV) and, currently, is not always treatable.

19 Apr 2022

How malaria drugs could play a part in treating chemotherapy-resistant head and neck cancers

In this interview, we speak to Kirill Kiselyov, Ph.D, and Umamaheswar Duvvuri, M.D, Ph.D, from the University of Pittsburgh, about their latest research into hydroxychloroquine, a drug widely used to prevent and treat malaria, as a potential treatment for head and neck cancers.

28 Mar 2022

Scientists describe use of PCR in detecting SARS-CoV-2 in paraffine-embedded tissues

Scientists compared the efficacy of the quantitative polymerase chain reaction method and immunohistochemistry in detecting SARS-CoV-2 in different human tissues.

25 Mar 2022

AI and machine learning could improve cancer diagnosis through biomarker discovery

Artificial intelligence (AI), deep learning (DL), and machine learning (ML) have transformed many industries and areas of science.

1 Mar 2022

Adding immunotherapy drug to standard head and neck cancer treatment increases patient survival

A University of Cincinnati clinical trial that added an immunotherapy drug to standard of care treatment regimens has shown increased survival rates for head and neck cancer patients with intermediate risk features.

1 Mar 2022

Merkel cell carcinoma has a higher post-treatment recurrence rate than other skin cancers

Patients treated for Merkel cell carcinoma (MCC) face a five-year recurrence rate of 40%-;markedly higher than the recurrence rates for melanoma and other skin cancers, according to research published today in JAMA Dermatology.

23 Feb 2022

Study demonstrates that TMPRSS2, which is key to SARS-CoV-2 cell entry, is a tumor suppressor

The role played by the host enzyme TMPRSS2 in infection and cancer is the focus of a new study.

23 Feb 2022

Researchers shows how ΔNp63 protein contributes to lung cancer development

Lung cancer is the second most common cancer in the U.S. and the No. 1 cause of cancer related death. Despite considerable progress in treatment options, most lung cancer patients have extremely poor outcomes with an average five-year survival rate of 21.7%.

12 Feb 2022

Deactivating the cancer-causing protein by cutting off other proteins that activate it

In a line of dominos, if you take out a single piece, the last one will never fall. Similarly, a lot of pieces have to line up and be pushed at the same time in a cell to result in cancer.

1 Dec 2021

Scientists link increased air pollution to an uptick in cases of lung cancer

An international team of scientists, led by Nanyang Technological University, Singapore (NTU Singapore), has linked increased air pollution to an uptick in cases of lung adenocarcinoma (LADC) worldwide.

25 Nov 2021

New therapeutic approach prevents growth of metastatic tumors by putting cancer cells to sleep

A new therapeutic approach prevents the growth of metastatic tumors in mice by forcing cancer cells into a dormant state in which they are unable to proliferate.

23 Nov 2021

Study identifies key factor sustaining malignant tumor state

In a study published in Nature Cancer, researchers led by Prof. Cedric Blanpain, WELBIO investigator, Director of the Laboratory of Stem Cells and Cancer and Professor at the Université libre de Bruxelles, Belgium, demonstrated that NR2F2 is an essential regulator of malignant tumor state by controlling cancer stem cell and tumor maintenance in mouse and human cancers.

22 Nov 2021

Potential therapeutic targets of hydrogen for treatment of the COVID-19

A recent article provided a review of a study led by academician Zhong Nanshan, in China, on COVID-19 treatment by inhalation of a mixed gas composed of hydrogen and oxygen.

12 Nov 2021

Scientists discover key component of cellular malfunction that contributes to growth of tumors

Scientists have homed in on a crucial step within the sequence of chemical reactions that govern regulation of cell division, proliferation and death, and whose malfunction contributes to the growth of tumors.

2 Nov 2021

Two new studies show how to enhance effectiveness of cancer immunotherapy

Two new studies revealed that anti-PD-1 immunotherapy given before surgery was safe and effective for patients with oral-cavity squamous cell carcinoma (OCSCC) and identified potential molecular biomarkers in the blood and tumors of patients that would show how likely it is that someone would respond to immunotherapy.

30 Oct 2021

Study reveals how to improve overall immune response against virally driven cancers

Blocking the PD-1 inhibitory pathway within a subset of specialized T-cells may improve overall immune response against virally driven cancers, according to findings published in Nature.

30 Sep 2021

Research provides the basis for an additional novel immunotherapy for multiple myeloma patients

Oncotarget published "Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma" which reported that Multiple Myeloma patients suffer disease relapse due to the development of therapeutic resistance. Increasing evidence suggests that immunotherapeutic strategies can provide durable responses.

29 Sep 2021

Penn Medicine and Wistar secure $11.7 million SPORE grant for three melanoma research projects

Penn Medicine and The Wistar Institute have been awarded a prestigious $11.7 million Specialized Programs of Research Excellence, or SPORE, grant from the National Cancer Institute.

22 Sep 2021